Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 3/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | IDH1 | O75874 | 3/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25781408 | 0.77 | MAP3K12 (0.43) | TRPV4JAK2TYK2 | |
| SCHEMBL31512322 | 0.75 | GRM5 (0.44) | MEN1KMT2AJAK2TYK2JAK3 | |
| SCHEMBL29783847 | 0.74 | CHEK1 (0.48) | TRPV4CHEK1MEN1KMT2AJAK2 | |
| SCHEMBL31512323 | 0.72 | ABCG2 (0.40) | JAK2TYK2JAK3KDM4EALDH1A1 | |
| SCHEMBL10549553 | 0.71 | ABCG2 (0.53) | MEN1KMT2AJAK2JAK3KDM4E | |
| SCHEMBL1959481 | 0.71 | GRM5 (0.43) | CHEK1KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL8989496 | 0.71 | TMPRSS4 (0.47) | TRPV4MEN1KMT2AJAK2TMPRSS4 | |
| SCHEMBL31512265 | 0.70 | JAK2 (0.39) | CHEK1JAK2TYK2JAK3 | |
| SCHEMBL24991566 | 0.70 | MEN1 (0.45) | TRPV4MEN1KMT2AJAK2TMPRSS4 | |
| SCHEMBL479494 | 0.70 | KDM4E (0.46) | TRPV4MEN1KMT2ATMPRSS4IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023168686-A1 | SUBSTITUTED CYCLOPENTANES AS CDK2 INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023116884-A1 | CDK2 INHIBITORS AND USE THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2023-06-29 | — | — | WO | disclosed |
| US-8168644-B2 | Quinazolinone derivatives as tubulin polymerization inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-01 | — | — | US | disclosed |
| EP-2260026-B1 | QUINAZOLINONE DERIVATIVES AS TUBULIN POLYMERIZATION INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-22 | — | — | EP | disclosed |
| US-20110028433-A1 | QUINAZOLINONE DERIVATIVES AS TUBULIN POLYMERIZATION INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028433-A1 | QUINAZOLINONE DERIVATIVES AS TUBULIN POLYMERIZATION INHIBITORS | TUBB3, TUBB1, TUBA1C | TRPV4 4661/4885CHEK1 842/4885MEN1 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.